Your browser doesn't support javascript.
loading
Girls with idiopathic central precocious puberty did not display substatial changes in body mass index after treatment with gonadotropin-releasing hormone analogues.
Uldbjerg, Cecilie Skaarup; Lim, Youn-Hee; Renault, Christoffer Højrup; Hansen, Dorte; Juul, Anders; Bräuner, Elvira Vaclavik; Jensen, Rikke Beck.
Afiliación
  • Uldbjerg CS; Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Lim YH; International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Renault CH; Department of Public Health, Section of Environmental Health, University of Copenhagen, Copenhagen, Denmark.
  • Hansen D; Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Juul A; Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Bräuner EV; International Centre for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
  • Jensen RB; Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark.
Acta Paediatr ; 113(7): 1602-1611, 2024 Jul.
Article en En | MEDLINE | ID: mdl-38506052
ABSTRACT

AIM:

To evaluate changes in body mass index (BMI) in girls during and after treatment for idiopathic central precocious puberty (iCPP).

METHODS:

We studied 123 girls receiving gonadotropin-releasing hormone analogue (GnRHa)treatment for iCPP from 2009 to 2019. Pubertal and anthropometric measurements were monitored at routine clinical visits. BMI standard deviation scores (SDS) were estimated at baseline and followed in two stages from baseline to end of treatment (median 18.9 months) and from end of treatment to end of follow-up (median 18.2 months). The influence of baseline BMI SDS and the frequency and dose of treatment was evaluated using BMI trajectories and latent class mixed models.

RESULTS:

The median age at treatment initiation was 8.5 years. The median BMI SDS at baseline was 0.7, corresponding to a median BMI of 17.4 kg/m2. Overall, no changes in BMI SDS were observed during treatment. According to baseline BMI subgroups, an increasing trend in BMI trajectories during treatment was observed for girls in the lowest BMI group. After treatment, most girls maintained stable BMI levels.

CONCLUSION:

Our retrospective study did not provide evidence that GnRHa treatment for iCPP had a significant impact on BMI trajectories in girls.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pubertad Precoz / Índice de Masa Corporal / Hormona Liberadora de Gonadotropina Límite: Child / Female / Humans Idioma: En Revista: Acta Paediatr Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Noruega
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pubertad Precoz / Índice de Masa Corporal / Hormona Liberadora de Gonadotropina Límite: Child / Female / Humans Idioma: En Revista: Acta Paediatr Año: 2024 Tipo del documento: Article País de afiliación: Dinamarca Pais de publicación: Noruega